About Intra-Cellular Therapies
Intra-Cellular Therapies is a company based in New York (United States) founded in 2002 by Sharon Mates was acquired by Johnson & Johnson in January 2025.. Intra-Cellular Therapies has raised $80.87 million across 9 funding rounds from investors including Johnson & Johnson, HHS and Military Health. The company has 600 employees as of December 31, 2023. Intra-Cellular Therapies operates in a competitive market with competitors including Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
- Headquarter New York, United States
- Employees 600 as on 31 Dec, 2023
- Founders Sharon Mates
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
$250.31 M199as on Dec 31, 2022
-
Net Profit
-
EBITDA
-
Total Equity Funding
$80.87 M (USD)
in 9 rounds
-
Latest Funding Round
$318.91 K (USD), Grant
Jul 01, 2014
-
Investors
Johnson & Johnson
& 2 more
-
Employee Count
600
as on Dec 31, 2023
-
Acquired by
Johnson & Johnson
(Jan 13, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Leadership Team
43 people
Sales and Marketing
15 people
Regional Team
14 people
Software Development Team
12 people
Senior Team
12 people
Product Management Team
11 people
Finance and Accounting
7 people
Human Resources and Administration
6 people
Unlock access to complete
Funding Insights of Intra-Cellular Therapies
Intra-Cellular Therapies has successfully raised a total of $80.87M across 9 strategic funding rounds. The most recent funding activity was a Grant round of $318.91 thousand completed in July 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Grant — $318,905
-
First Round
First Round
(01 Mar 2003)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2014 | Amount | Grant - Intra-Cellular Therapies | Valuation |
investors |
|
| Aug, 2013 | Amount | Series C - Intra-Cellular Therapies | Valuation |
investors |
|
| Apr, 2013 | Amount | Series B - Intra-Cellular Therapies | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Intra-Cellular Therapies
Intra-Cellular Therapies has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Johnson & Johnson, HHS and Military Health. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location | |
|
Administers health care and support for military personnel and operations.
|
Founded Year | Domain | Location | |
|
Healthcare solutions are provided by Johnson & Johnson globally.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Intra-Cellular Therapies
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Intra-Cellular Therapies
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Intra-Cellular Therapies Comparisons
Competitors of Intra-Cellular Therapies
Intra-Cellular Therapies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
Biologics platform developed for intracellular delivery in rare diseases.
|
|
| domain | founded_year | HQ Location |
Pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics.
|
|
| domain | founded_year | HQ Location |
T-cell-based therapies for autoimmune and degenerative diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Intra-Cellular Therapies
Frequently Asked Questions about Intra-Cellular Therapies
When was Intra-Cellular Therapies founded?
Intra-Cellular Therapies was founded in 2002 and raised its 1st funding round 1 year after it was founded.
Where is Intra-Cellular Therapies located?
Intra-Cellular Therapies is headquartered in New York, United States. It is registered at New York, New York, United States.
Who is the current CEO of Intra-Cellular Therapies?
Sharon Mates is the current CEO of Intra-Cellular Therapies. They have also founded this company.
Is Intra-Cellular Therapies a funded company?
Intra-Cellular Therapies is a funded company, having raised a total of $80.87M across 9 funding rounds to date. The company's 1st funding round was a Series B of $241.63K, raised on Mar 01, 2003.
How many employees does Intra-Cellular Therapies have?
As of Dec 31, 2023, the latest employee count at Intra-Cellular Therapies is 600.
What is the annual revenue of Intra-Cellular Therapies?
Annual revenue of Intra-Cellular Therapies is $250.31M as on Dec 31, 2022.
What does Intra-Cellular Therapies do?
Developer of therapeutics for psychiatric and neurologic diseases. The companys lead product, ITI-007 is a novel first-in-class 5-HT2A antagonist, Dopamine receptor phosphoprotein modulator (DPPM) designed to treat multiple deficits in patients with schizophrenia while lacking the side-effects of existing antipsychotic drugs. It also developed a state of the art technology platform, called CNSProfil that is capable of generating a unique molecular signature for drug compounds.
Who are the top competitors of Intra-Cellular Therapies?
Intra-Cellular Therapies's top competitors include Alector, Entrada Therapeutics and Annexon.
Who are Intra-Cellular Therapies's investors?
Intra-Cellular Therapies has 3 investors. Key investors include Johnson & Johnson, HHS, and Military Health.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.